Can a patient with elevated alkaline phosphatase levels start Forteo (teriparatide) for osteoporosis treatment?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 30, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Can You Start Forteo in a Patient with Elevated Alkaline Phosphatase?

You should NOT start Forteo (teriparatide) in a patient with elevated alkaline phosphatase until you have determined the cause of the elevation and ruled out contraindications, particularly Paget's disease and bone malignancy. 1

Critical Contraindications Related to Elevated ALP

Teriparatide is absolutely contraindicated in several conditions that present with elevated alkaline phosphatase:

  • Paget's disease of bone is an absolute contraindication to teriparatide therapy, as the drug's anabolic effects could worsen the already excessive bone turnover characteristic of this condition 2, 1
  • Bone malignancy or skeletal metastases represent absolute contraindications due to teriparatide's black box warning for potential osteosarcoma risk 1
  • Unexplained elevation of alkaline phosphatase itself is listed as a contraindication in FDA labeling, as it may indicate underlying Paget's disease or malignancy 1

Mandatory Workup Before Considering Teriparatide

Before initiating teriparatide in any patient with elevated ALP, you must complete this diagnostic evaluation:

Determine the Source of ALP Elevation

  • Measure bone-specific alkaline phosphatase (B-ALP) to confirm bone origin, as this is more specific than total ALP 2
  • Obtain liver function tests including GGT—if GGT is normal, this strongly indicates a non-hepatic (bone) source 2
  • Check serum calcium, phosphate, and PTH to assess for metabolic bone disorders 2
  • Measure 25-hydroxyvitamin D levels to evaluate for vitamin D deficiency and osteomalacia 3, 2

Rule Out Malignancy

  • Perform bone scintigraphy as the primary imaging modality if malignancy is suspected or if ALP remains unexplained 2, 4
  • Obtain targeted radiographs to assess for lytic lesions or other concerning bone pathology 2, 4
  • Measure lactate dehydrogenase (LDH) as elevated levels correlate with bone malignancy and metastatic disease 4

Rule Out Paget's Disease

  • Clinical assessment for bone pain, deformity, or warmth over affected bones 5
  • Radiographic evaluation for characteristic findings of Paget's disease (cortical thickening, trabecular coarsening) 5
  • Bone scan if Paget's disease is suspected clinically 2

When Teriparatide May Be Appropriate

If your workup reveals a benign cause of elevated ALP, teriparatide may be considered:

  • Post-fracture healing causes physiologic ALP elevation that typically normalizes within 2-3 months; teriparatide can be initiated once healing is confirmed and ALP is trending down 2
  • Vitamin D deficiency/osteomalacia should be corrected first with vitamin D supplementation before starting teriparatide 3, 2
  • Hypophosphatasia is a rare exception where teriparatide has been used successfully despite low baseline ALP, though this represents a unique clinical scenario 6

Important Clinical Caveat

One case report documented extreme ALP elevation (6480 U/L) during teriparatide treatment in a young patient with glucocorticoid-induced osteoporosis, suggesting potential osteoblast hyperactivation 7. While this is rare, it underscores the importance of:

  • Monitoring ALP levels every 4-6 weeks during the first few months of teriparatide therapy 2
  • Discontinuing teriparatide immediately if ALP rises dramatically or unexpectedly during treatment 7
  • Exercising particular caution in younger patients or those with complex medical conditions 7

Alternative Treatment Options

If teriparatide is contraindicated or the elevated ALP remains unexplained, consider these alternatives:

  • Bisphosphonates (alendronate 70mg weekly, risedronate 35mg weekly, or zoledronic acid 5mg IV annually) are first-line therapy for osteoporosis and do not carry the same contraindications 1
  • Denosumab (60mg subcutaneous every 6 months) works through a different mechanism and may be appropriate 1

Bottom line: Do not start Forteo until you have a clear explanation for the elevated ALP and have definitively ruled out Paget's disease and malignancy.

References

Guideline

Teriparatide Contraindications in Hypoparathyroidism

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Elevated Alkaline Phosphatase After Back Surgery

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Laboratory Tests for Suspected Lower Extremity Bone Cancer

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.